Abbonarsi

Radiofrequency ablation for long- and ultralong-segment Barrett's esophagus: a comparative long-term follow-up study - 19/03/13

Doi : 10.1016/j.gie.2012.10.021 
Parambir S. Dulai, MD 1, ⁎, Heiko Pohl, MD 2, John M. Levenick, MD 2, Stuart R. Gordon, MD 2, Todd A. MacKenzie, PhD 1, Richard I. Rothstein, MD 1, 2
1 Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA 
2 Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA 

Reprint requests: Parambir S. Dulai, MD, Department of Medicine, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756

Riassunto

Background

The safety, efficacy, and durability of radiofrequency ablation (RFA), with or without EMR, have been established for long-segment Barrett's esophagus (LSBE). Ablating ultralong-segment Barrett's esophagus (ULSBE) may be associated with increased stricture formation, eradication failure, and treatment session requirements.

Objectives

Our primary objective was to compare eradication and stricture rates between LSBE (≥3 to <8 cm) and ULSBE (≥8 cm). Our secondary objective was to evaluate treatment durability and session requirements.

Design

Retrospective review of prospectively collected data.

Setting

Tertiary care facility.

Patients

A total of 72 patients (34 ULSBE, 38 LSBE; mean Barrett's segment length of 10.8 and 4.7 cm) underwent RFA between August 2005 and September 2010. Mean follow-up was 45 and 34 months, respectively.

Main Outcome Measurements

Eradication and complication rates for ULSBE and LSBE.

Results

Eradication rates for dysplasia (90% vs 88%, P = 1.0) and intestinal metaplasia (IM) (77% vs 82%, P = .77) were similar. ULSBE patients required more overall (P < .01) and circumferential (P < .01) RFA; however, stricture rates were identical (14%). There was no dysplasia recurrence, and IM recurrence was similar (ULSBE, 23%; LSBE, 16%; P = .52). At 3 years, IM remained eradicated in 65% of ULSBE and 82% of LSBE, without maintenance RFA. On multivariate regression analysis, increasing Barrett's length was associated with a reduced likelihood for eradicating IM (odds ratio 0.87; 95% CI, 0.75-1.00), but not dysplasia (odds ratio 1.13; 95% CI, 0.95-1.35).

Limitations

Single center.

Conclusion

ULSBE can be treated in its entirety at each session with efficacy and safety comparable to LSBE. ULSBE requires more effort to achieve IM eradication, and RFA is less durable in maintaining this eradication at 3-year follow-up.

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : BE, CE-D, CE-IM, HGD, IM, LSBE, RFA, ULSBE


Mappa


 DISCLOSURE: The following authors disclosed financial relationships relevant to this publication: Drs Rothstein and Gordon have received research support from BARRX Medical Inc (NEJM 2009 May;360(22):2277-88; Gastroenterology 2011 Aug;141(2):460-8). The other authors disclosed no financial relationships relevant to this publication.
 If you would like to chat with an author of this article, you may contact Dr Dulai at [email protected].


© 2013  American Society for Gastrointestinal Endoscopy. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 77 - N° 4

P. 534-541 - aprile 2013 Ritorno al numero
Articolo precedente Articolo precedente
  • EUS-guided pancreatic cyst ablation: a critical review (with video)
  • Hyoung-Chul Oh, William R. Brugge
| Articolo seguente Articolo seguente
  • The role of high-resolution endoscopy and narrow-band imaging in the evaluation of upper GI neoplasia in familial adenomatous polyposis
  • Maria Lopez-Ceron, Frank J.C. van den Broek, Elisabeth M. Mathus-Vliegen, Karam S. Boparai, Susanne van Eeden, Paul Fockens, Evelien Dekker

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.